Filana Gets FDA Green Light for Phase 2a Simufilam Study in TSC-Related Epilepsy

FDA lifted the clinical hold on Filana’s simufilam, clearing a Phase 2a study in TSC-related epilepsy. Lucid Capital keeps a Buy rating and $8 target.